Motilal Oswal initiates coverage on Molbio Diagnostics with buy, Rs 1,800 target

The Story in Brief

Motilal Oswal Financial Services has initiated coverage on Molbio Diagnostics with a 'buy' rating and a target price of Rs 1,800, implying a 19 to 21 percent upside from recent closing prices, according to reports from CNBC TV18, NDTV Profit, Livemint, the Economic Times and Hindu Business Line. In a bull-case scenario, the brokerage sees a target of Rs 2,575, implying a 70 percent upside, while the bear-case target is Rs 1,100. All three analysts covering the stock have a 'buy' rating, with Jefferies at Rs 1,600 and IIFL at Rs 1,550. The stock was trading around Rs 1,475 to 1,543 on 6 to 7 October, up over 80 percent from its IPO price of Rs 807.

Motilal Oswal initiates coverage on Molbio Diagnostics with buy rating

The brokerage expects Molbio's revenue to grow at a 23 percent CAGR over FY26-29, driven by higher utilisation of its TrueNat platform, which has over 12,500 devices across 90 countries and 43 assays covering 30 diseases, and expansion into digital pathology and imaging. Motilal Oswal identified dependence on government orders, customer concentration, and elevated working capital as key risks. The brokerage noted that successful diversification beyond TB, stronger international adoption and improving cash conversion could support a re-rating.

Update, 8 October 2026: The Hindu Business Line now also reports the coverage initiation with identical figures and risks. It states the current market price was Rs 1,543.75 and lists customer concentration, high revenue contribution of TB testing, delays in regulatory approvals and slower-than-expected adoption of Truenat as key risks.

Indian Opinion Analysis

Motilal Oswal initiated coverage of Molbio Diagnostics with a 'buy' rating and a base target price of Rs 1,800, implying an upside of 19 to 21 percent from recent closing prices, CNBC TV18, NDTV Profit, Livemint, the Economic Times and Hindu Business Line report. The brokerage sees a bull-case target of Rs 2,575 and a bear-case target of Rs 1,100 across all five reports. CNBC TV18 and the Economic Times emphasise the global opportunity: the USD 9.3 billion point-of-care infectious-disease testing market growing at 23 percent and Molbio's 12,500 devices across 90 countries. NDTV Profit and Livemint highlight that the stock has already risen over 80 percent from its Rs 807 IPO price in less than two months and fell more than 2 percent on 6 October.

Coverage: 5 sources, 5 neutral


Sources (5): cnbctv18.com (neutral report), ndtvprofit.com (neutral report), livemint.com (neutral report), economictimes.indiatimes.com (neutral report), thehindubusinessline.com (neutral report)

This brief was synthesised by AI from the 5 sources linked above, so one read covers every framing they carry. Methodology and corrections.

Ask their opinion on this story
They have read this article, our coverage, and the web.
AI simulations of historical figures. Responses are generated from the historical record, not authentic statements.

0 Votes: 0 Upvotes, 0 Downvotes (0 Points)

Share your opinion

Sign in to comment

Comments are open to readers with an Indian Opinion account. We email you a 6-digit code; there is no password.

Sign in to comment

Loading Next Post...
Search Trending
Ask their opinion
Loading

Signing-in 3 seconds...

Signing-up 3 seconds...

All fields are required.